Table 1.
Clinical and demographic characteristics of the study cohort.
| MS subjects (N = 125) | Healthy controls(N = 24) | |
|---|---|---|
| Gender, n (%) | ||
| Female | 69 (55.2) | 13 (54.2) |
| Male | 56 (44.8) | 11 (45.8) |
| Age, years | ||
| Mean age (±SD) | 41 (±10.7) | 47.3 (±11) |
| 25–75 IQR | 16.5 | 20.5 |
| MS type, n (%) | ||
| RRMS | 117 (93.6) | |
| PPMS | 4 (3.2) | |
| SPMR | 4 (3.2) | |
| EDSS, n (%) | ||
| ≤3.0 | 104 (83.2) | |
| 3.5–5.5 | 17 (13.6) | |
| ≥6.0 | 4 (3.2) | |
| DMT type, n (%) | ||
| Interferon β 1a | 22 (17.6) | |
| Dimethyl fumarate | 18 (14.4) | |
| Teriflunomide | 10 (8.0) | |
| Natalizumab | 22 (17.6) | |
| Glatiramer acetate | 9 (7.2) | |
| Cladribine | 10 (8.0) | |
| Fingolimod | 19 (15.2) | |
| Ocrelizumab | 15 (12.0) | |
| DMT duration, mean (months) | ||
| Interferon β 1a | 82.1 | |
| Dimethyl fumarate | 45.4 | |
| Teriflunomide | 29.7 | |
| Natalizumab | 52 | |
| Glatiramer acetate | 61.4 | |
| Cladribine | 14.8 | |
| Fingolimod | 55.5 | |
| Ocrelizumab | 24.2 | |
| Last 12-months relapse, n (%) | 23 (18.4) |
DMTs: disease-modifying therapies; EDSS: Expanded Disability Status Scale; MS: Multiple Sclerosis; PPMS: Primary Progressive Multiple Sclerosis; RRMS: Relapsing Remitting Multiple Sclerosis; SPSM: Secondary Progressive Multiple Sclerosis.